Частота рецидивов ретинопатии недоношенных после интравитреальной инъекции афлиберцепта в зависимости от гестационного возраста

Abstract

Material and methods. This study was conducted at the V.F. Voino-Yasenetsky Scientific and Practical Center for Specialized Medical Care in Children from September 2021 to February 2023. The study included 122 premature infants (244 eyes) with retinopathy of prematurity who received intravitreal administration of aflibercept. All patients were divided into 3 groups depending on gestational age, including a group of patients with a gestational age of less than 27 weeks (70 eyes), a group of patients with a gestational age of 27 to 29 weeks (106 eyes) and a group of patients with a gestational age of from 29 weeks (68 eyes). All patients were monitored for reactivation of retinopathy of prematurity after intravitreal aflibercept injection. Results. The overall relapse rate after treatment was 37/244 eyes (15.16%); The reactivation rate of the gestational age >29 weeks group was 5.88% of the middle gestational age group – 9.43% and the low gestational age group (<27 weeks) – 32.86% respectively. The reactivation time in the three groups of patients was 10.75±5.03 weeks for the low gestational age group, 7.40±4.04 weeks for the middle gestational age group, and 15,00±11,31 weeks for the high gestational age group. Conclusion. Intravitreal injection of aflibercept is an effective treatment for ROP. The younger the gestational age, the more often and faster reactivation of ROP occurs after injections of angiogenesis inhibitors. Key words: recurrence, reactivation, retinopathy of prematurity, risk factor, gestational age, intravitreal injection, aflibercept, vascular endothelial growth factor, angiogenesis inhibitors